These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9803831)

  • 1. Steroidal and nonsteroidal oestrogen antagonists in breast cancer: basic and clinical appraisal.
    Favoni RE; de Cupis A
    Trends Pharmacol Sci; 1998 Oct; 19(10):406-15. PubMed ID: 9803831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New vs old fashioned oestradiol antagonists in mammary carcinoma: 'in vitro' and 'in vivo' pharmacological approaches.
    de Cupis A; Schettini G; Favoni RE
    Pharmacol Res; 1999 May; 39(5):335-44. PubMed ID: 10328990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oestrogen/growth factor cross-talk in breast carcinoma: a specific target for novel antioestrogens.
    de Cupis A; Favoni RE
    Trends Pharmacol Sci; 1997 Jul; 18(7):245-51. PubMed ID: 9253856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The elucidation of the antiestrogen and antitumoral mechanisms of tamoxifen].
    Borgna JL
    Bull Cancer; 1994 Jan; 81(1):29-37. PubMed ID: 7949581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oestrogenic activity of tamoxifen and its metabolites on gene regulation and cell proliferation in MCF-7 breast cancer cells.
    Johnson MD; Westley BR; May FE
    Br J Cancer; 1989 May; 59(5):727-38. PubMed ID: 2736207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects and mechanism of action of antiestrogens in breast cancer].
    Borgna JL; Rochefort H
    Pathol Biol (Paris); 1983 Nov; 31(9):775-81. PubMed ID: 6361675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance.
    Johnston SR; Riddler S; Haynes BP; A'Hern R; Smith IE; Jarman M; Dowsett M
    Br J Cancer; 1997; 75(6):804-9. PubMed ID: 9062399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular aspects of different mechanisms of tamoxifen resistance].
    Bachmann-Moisson N; Barberi-Heyob M; Merlin JL
    Bull Cancer; 1997 Jan; 84(1):69-75. PubMed ID: 9180863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-affinity anti-oestrogen binding site distinct from the oestrogen receptor.
    Sutherland RL; Murphy LC; San Foo M; Green MD; Whybourne AM; Krozowski ZS
    Nature; 1980 Nov; 288(5788):273-5. PubMed ID: 7432524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer.
    Nicholson RI; Hutcheson IR; Hiscox SE; Knowlden JM; Giles M; Barrow D; Gee JM
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S29-36. PubMed ID: 16113097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-estrogens and bone tissue].
    Ribot C; Trémollières F
    Ann Endocrinol (Paris); 1995; 56(6):603-8. PubMed ID: 8787352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pure anti-oestrogens.
    Hermenegildo C; Cano A
    Hum Reprod Update; 2000; 6(3):237-43. PubMed ID: 10874568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A molecular strategy to control tamoxifen resistant breast cancer.
    Jiang SY; Jordan VC
    Cancer Surv; 1992; 14():55-70. PubMed ID: 1423331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of tamoxifen resistance.
    Ring A; Dowsett M
    Endocr Relat Cancer; 2004 Dec; 11(4):643-58. PubMed ID: 15613444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative mechanisms of action of anti-oestrogens.
    Colletta AA; Benson JR; Baum M
    Breast Cancer Res Treat; 1994; 31(1):5-9. PubMed ID: 7981456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
    Robertson JF; Come SE; Jones SE; Beex L; Kaufmann M; Makris A; Nortier JW; Possinger K; Rutqvist LE
    Eur J Cancer; 2005 Feb; 41(3):346-56. PubMed ID: 15691633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines.
    Müller V; Jensen EV; Knabbe C
    Cancer Res; 1998 Jan; 58(2):263-7. PubMed ID: 9443403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High progesterone receptor concentration in a variant of the ZR-75-1 human breast cancer cell line adapted to growth in oestrogen free conditions.
    van den Berg HW; Martin J; Lynch M
    Br J Cancer; 1990 Apr; 61(4):504-7. PubMed ID: 2139575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells.
    Murphy LC; Peng B; Lewis A; Davie JR; Leygue E; Kemp A; Ung K; Vendetti M; Shiu R
    J Mol Endocrinol; 2005 Apr; 34(2):553-66. PubMed ID: 15821116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pure oestrogen antagonists for the treatment of advanced breast cancer.
    Howell A
    Endocr Relat Cancer; 2006 Sep; 13(3):689-706. PubMed ID: 16954425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.